An Open-label Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Odalasvir (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 05 Oct 2017 Planned End Date changed from 31 May 2017 to 31 Dec 2017.
- 05 Oct 2017 Planned primary completion date changed from 31 May 2017 to 31 Dec 2017.
- 09 Dec 2016 Status changed from not yet recruiting to recruiting.